Últimas noticias sobre Aspen Aerogels (NYSE:ASPN) Bolsa

Aspen Aerogels

Aspen Aerogels Inc is an aerogel technology company that designs, develops, and manufactures high-performance aerogel insulation used in the energy industrial and sustainable insulation markets. The company also conducts research and development related to aerogel technology supported by funding from several agencies of the United States of America government and other institutions in the form of research and development contracts. It is engaged in two operating segment Energy Industrial and Thermal Barrier. Geographically, it operates in the U.S. and also has a presence in other International countries. It generates the majority of its revenue from the Energy Industrial segment and the United States market. Some of its products include Pyrogel XTE; Cryogel Z; Spaceloft Subsea; and others.

News

Downgrades

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

ASPN

Los analistas de Wall Street degradaron varias acciones clave. Descubre cuáles y cómo podría impactar en el mercado.

Grandes cambios en calificaciones de acciones: ¿Cómo afectará a tu cartera de inversión?

Short Ideas

UAMY

Tres acciones de materiales con niveles de RSI sobrecomprados, incluyendo Aspen Aerogels, AngloGold Ashanti y United States Antimony.

3 acciones de materiales que podrían colapsar en el tercer trimestre

Aspen Aerogels Inc

U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 0.1% on Thursday.
Shares of The Trade Desk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) fell sharply in today's pre-market trading after the company reported <a href="https://in.benzinga.com/news/earnings/25/02/43675459/the-trade-desk-stock-drops-after-q4-revenues-miss-estimates-details">worse-than-expected quarterly revenue results.</a>
Trade Desk reported quarterly earnings of 59 cents per share, which beat the analyst consensus estimate of 56 cents. Quarterly revenue came in at $741.01 million, which missed the analyst consensus estimate of $758.93 million.
Trade Desk shares tumbled 27% to $89.34 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Aspen Aerogels, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) shares fell 30.6% to $8.15 in pre-market trading after the company issued first-quarter guidance below estimates.</li>
<li>Fastly, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSLY#NYSE">FSLY</a>) shares tumbled 20.6% to $8.00 in pre-market trading. Fastly reported a fourth-quarter loss of 3 cents per share, down from earnings of 1 cent per share in the prior year&#8217;s quarter. Quarterly revenue came in at $140.58 million, beating the $138.27 million analyst consensus estimate. Fastly expects first-quarter losses of between 9 cents and 5 cents per share, versus the loss of 1 cent estimate, and revenue in a range of $136 million to $140 million, versus the $137.05 million estimate.</li>
<li>Atai Life Sciences N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) fell 14.5% to $2.1800 in pre-market trading after the company announced the pricing of public offering of common shares.</li>
<li>Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) fell 14.1% to $185.94 in pre-market trading after the company reported fourth-quarter results.</li>
<li>Open Lending Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPRO#NASDAQ">LPRO</a>) shares dipped 13% to $5.02 in pre-market trading.</li>
<li>British American Tobacco p.l.c. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTI#NYSE">BTI</a>) fell 9.6% to $38.66 in pre-market trading.</li>
<li>Unilever PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UL#NYSE">UL</a>) declined 6.8% to $55.14 in pre-market trading as the company reported 2024 underlying sales growth of 4.2%.</li>
<li>Pegasystems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGA#NASDAQ">PEGA</a>) fell 6.2% to $99.50 in pre-market trading following fourth-quarter results.</li>
<li>Lionsgate Studios Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LION#NASDAQ">LION</a>) slipped 3.3% to $8.27 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43655479/top-3-utilities-stocks-that-may-collapse-in-q1">Top 3 Utilities Stocks That May Collapse In Q1</a></li>
</ul>

Movers

ATAI

FSLY

LION

LPRO

PEGA

RDDT

Trade Desk Posts Downbeat Revenue, Joins Aspen Aerogels, Fastly And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Evercore ISI Group analyst Shweta Khajuria downgraded the rating for The Trade Desk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) from Outperform to In-Line and lowered the price target from $135 to $90. Trade Desk shares closed at $122.23 on Wednesday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Seaport Global analyst Tom Curran downgraded the rating for Aspen Aerogels, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) from Buy to Neutral. Aspen Aerogels shares closed at $11.75 on Wednesday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler analyst Charles Neivert downgraded Olin Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLN#NYSE">OLN</a>) from Overweight to Neutral and lowered the price target from $41 to $33. Olin shares closed at $27.98 on Wednesday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Matthew Weston downgraded the rating for Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) from Buy to Neutral. Novartis shares closed at $107.00 on Wednesday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Bryan Spillane downgraded The Kraft Heinz Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>) from Buy to Underperform and lowered the price target from $36 to $33. Kraft Heinz shares closed at $28.62 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying KHC stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13075746/image-2-39-1024x576.png" alt="" class="wp-image-780861" style="width:546px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13075746/image-2-39-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13075746/image-2-39-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13075746/image-2-39-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13075746/image-2-39.png 1106w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43655479/top-3-utilities-stocks-that-may-collapse-in-q1">Top 3 Utilities Stocks That May Collapse In Q1</a></li>
</ul>

This Kraft Heinz Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday

WIIM

Aspen Aerogels shares are trading lower after Seaport Global downgraded the stock from Buy to Neutral.

Seaport Global analyst Tom Curran downgrades Aspen Aerogels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) from Buy to Neutral.

Seaport Global Downgrades Aspen Aerogels to Neutral

Shares of AppLovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) rose sharply in today's pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued first-quarter revenue guidance <a href="https://www.benzinga.com/news/earnings/25/02/43676556/applovin-stock-soars-on-q4-earnings-revenue-beat-eps-beat-strong-guidance-and-more">above estimates</a>.
Applovin reported fourth-quarter revenue of $1.37 billion, beating analyst estimates of $1.26 billion, according to Benzinga Pro. The company reported fourth-quarter earnings of $1.73 per share, beating analyst estimates of $1.25 per share.
AppLovin shares jumped 28.9% to $490.10 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Phoenix Motor Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEV#NASDAQ">PEV</a>) gained 81.2% to $0.4570 in pre-market trading after the company said third-quarter revenue jumped 1,557% year-over-year to $4.77 million.</li>
<li>Tivic Health Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) rose 42% to $0.9937 in pre-market trading. Tivic Health Systems shares jumped 198% on Wednesday after the company announced it acquired the exclusive license rights from Statera Biopharma for its Phase III TLR5 agonist entolimod treatment of acute radiation syndrome.</li>
<li>Avinger, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ">AVGR</a>) shares jumped 45.6% to $0.6701 in pre-market trading.</li>
<li>MGO Global, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGOL#NASDAQ">MGOL</a>) gained 38.5% to $0.6326 in pre-market trading after dipping 24% on Wednesday.</li>
<li>ProPhase Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) gained 26% to $0.3535 in pre-market following a 7% gain in the previous session.</li>
<li>Dutch Bros Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) shares climbed 24.6% to $80.72 in pre-market trading following better-than-expected fourth-quarter financial results.</li>
<li>Twin Disc, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWIN#NASDAQ">TWIN</a>) gained 19.4% to $11.99 in pre-market trading after dipping 10% on Wednesday.</li>
<li>Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) gained 15.6% to $64.72 in pre-market trading after the company reported better-than-expected quarterly financial results.</li>
<li>CEVA, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CEVA#NYSE">CEVA</a>) gained 8.5% to $34.41 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Aspen Aerogels, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) shares fell 30.6% to $8.15 in pre-market trading after the company issued first-quarter guidance below estimates.</li>
<li>The Trade Desk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) dipped 27% to $89.34 in pre-market trading after the company reported worse-than-expected quarterly revenue results.</li>
<li>Omega Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMGA#NASDAQ">OMGA</a>) fell 24.6% to $0.1960 in today's pre-market trading after surging 35% on Wednesday. Omega Therapeutics' restructuring committee recently approved a workforce reduction of up to 17 employees for cost-reduction amid a Chapter 11 case and potential asset sale.</li>
<li>NKGen Biotech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) shares fell 24.4% to $0.6363 in pre-market trading. NKGen Biotech shares jumped 122% on Wednesday after the company received FDA Fast Track designation for Troculeucel for the treatment of moderate Alzheimer&#8217;s disease.</li>
<li>Mynaric AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNA#NASDAQ">MYNA</a>) fell 23.7% to $0.4730 in pre-market trading after jumping 134% on Wednesday.</li>
<li>Fastly, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSLY#NYSE">FSLY</a>) shares tumbled 20.6% to $8.00 in pre-market trading. Fastly reported a fourth-quarter loss of 3 cents per share, down from earnings of 1 cent per share in the prior year&#8217;s quarter. Quarterly revenue came in at $140.58 million, beating the $138.27 million analyst consensus estimate. Fastly expects first-quarter losses of between 9 cents and 5 cents per share, versus the loss of 1 cent estimate, and revenue in a range of $136 million to $140 million, versus the $137.05 million estimate.</li>
<li>Solaris Resources Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLSR#NYSE">SLSR</a>) declined 18.1% to $3.30 in pre-market trading.</li>
<li>Atai Life Sciences N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) fell 14.5% to $2.1800 in pre-market trading after the company announced the pricing of public offering of common shares.</li>
<li>Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) fell 14.1% to $185.94 in pre-market trading after the company reported fourth-quarter results.</li>
<li>Open Lending Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPRO#NASDAQ">LPRO</a>) shares dipped 13% to $5.02 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43655479/top-3-utilities-stocks-that-may-collapse-in-q1">Top 3 Utilities Stocks That May Collapse In Q1</a></li>
</ul>

AVGR

BROS

CEVA

HOOD

MGOL

MYNA

NKGN

OMGA

PRPH

SLSR

TIVC

TWIN

Why AppLovin Shares Are Trading Higher By Around 29%; Here Are 20 Stocks Moving Premarket

Aspen Aerogels shares are trading lower after the company issued Q1 guidance below estimates.

Aspen Aerogels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) Q1 expected to be more than $(0.18) vs $0.07 Est. sees Q1 sales of $75.000 million-$95.000 million vs $104.22 million analyst estimate.

Guidance

Aspen Aerogels Q1 EPS expected to be more than $(0.18) vs $0.07 Est; Sees Q1 Sales $75.000M-$95.000M vs $104.22M Est

Aspen Aerogels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.08 by 75 percent. This is a 1500 percent increase over losses of $(0.01) per share from the same period last year. The company reported quarterly sales of $123.09 million which beat the analyst consensus estimate of $120.80 million by 1.89 percent. This is a 46.15 percent increase over sales of $84.22 million the same period last year.

Earnings

Earnings Beats

Aspen Aerogels Q4 EPS $0.14 Beats $0.08 Estimate, Sales $123.09M Beat $120.80M Estimate

ACRE

AEIS

AEMD

ALCO

ALKS

AMWL

ASND

ATRC

AVXL

AYTU

BIIB

BXMT

CAMT

CGNX

CHEF

CNCK

CNDT

COOP

CRBG

CRSR

CRWS

CSCO

CTRE

CWST

DENN

EPRT

EQIX

FCPT

GAIN

GILT

GLPG

GNRC

GOLD

GROW

HCSG

HUBS

IREN

KRNT

MKSI

MLYS

MMLP

NMTC

OPRT

OTLY

PAYC

PLMR

PODC

PXLW

PYPD

QDEL

QMCO

QTWO

Earnings Scheduled For February 12, 2025

This settlement concludes Aspen's legal action against AMA regarding the unauthorized sale of infringing aerogel insulation materials in Europe.

Legal

Aspen Aerogels Reaches Agreement To Resolve Its Patent Dispute With AMA; No Terms Disclosed

Canaccord Genuity analyst George Gianarikas maintains Aspen Aerogels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) with a Buy and lowers the price target from $28 to $20.

Price Target

Canaccord Genuity Maintains Buy on Aspen Aerogels, Lowers Price Target to $20

The most oversold stocks in the materials sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Aspen Aerogels Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>)</h3>
<ul>
<li>On Nov. 6, Aspen Aerogels reported better-than-expected third-quarter revenue results.. The company's stock fell around 31% over the past month and has a 5<a href="https://www.benzinga.com/quote/ASPN">2-week low of $10.31</a>.</li>
<li>RSI Value: 26.83&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>ASPN Price Action: Shares of Aspen Aerogels rose 0.1% to close at $14.00 on Thursday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112224&amp;t=be2bearmibe3na1">ASPN news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="897" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22071409/image-239.png" alt="" class="wp-image-660788" style="width:640px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22071409/image-239.png 897w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22071409/image-239-300x283.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22071409/image-239-768x725.png 768w" sizes="(max-width: 897px) 100vw, 897px" /></a></figure>
<h3 class="wp-block-heading">Braskem SA ADR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAK#NYSE">BAK</a>)&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On Sept. 18, UBS upgraded the stock from Neutral to Buy and raised its price target from $7.7 to $10. The company's stock fell around 36% over the past month and<a href="https://www.benzinga.com/quote/bak"> has a 52-week</a> low of $64.98.</li>
<li>RSI Value: 18.13</li>
<li>BAK Price Action: Shares of Braskem fell 2.4% to close at $4.96 on Wednesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112224&amp;t=be2bearmibe3na1">BAK stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="916" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22071554/image-240.png" alt="" class="wp-image-660794" style="width:746px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22071554/image-240.png 916w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22071554/image-240-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22071554/image-240-768x710.png 768w" sizes="(max-width: 916px) 100vw, 916px" /></a></figure>
<h3 class="wp-block-heading">TMC the metals company Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMC#NASDAQ">TMC</a>)</h3>
<ul>
<li>On Nov. 14, TMC Metals posted third-quarter loss of 6 cents per share. Gerard Barron, Chairman &amp; CEO of The Metals Company commented, "This week we announced June 27, 2025, as the date for NORI to submit its exploitation application to the ISA. This decision, made in close consultation with NORI&#8217;s Sponsoring State Nauru, represents years of preparation, backed by the largest dataset ever collected on the deep sea in international waters. We&#8217;re excited to share our application with the ISA and stakeholders and recognize the responsibility that comes with submitting the world&#8217;s first application of this kind." The company's stock fell around 13% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/tmc">low of $0.80</a>.</li>
<li>RSI Value: 28.06</li>
<li>TMC Price Action: Shares of TMC the metals company fell 2.1% to close at $0.88 on Thursday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112224&amp;t=be2bearmibe3na1">breakout in TMC shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="878" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22071859/image-241.png" alt="" class="wp-image-660802" style="width:718px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22071859/image-241.png 878w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22071859/image-241-300x289.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22071859/image-241-768x741.png 768w" sizes="(max-width: 878px) 100vw, 878px" /></a></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42131399/dow-surges-over-450-points-investor-sentiment-improves-fear-greed-index-moves-to-greed-zone">Dow Surges Over 450 Points As Nvidia Climbs Post-Earnings, Google, Amazon Slip: Fear Index Shifts To &#8216;Greed&#8217; Zone</a></li>
</ul>

Long Ideas

Top 3 Materials Stocks That Could Blast Off In November

Aspen Aerogels shares are trading lower after Barclays cut its price target on the stock from $27 to $25.

Throughout the last three months, 6 analysts have evaluated Aspen Aerogels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>), offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $32.67, a high estimate of $41.00, and a low estimate of $25.00. A 2.48% drop is evident in the current average compared to the previous average price target of $33.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1731427258_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive Aspen Aerogels is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Chip Moore</td>
<td>Roth MKM</td>
<td>Lowers</td>
<td>Buy</td>
<td>$31.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Alexander Potter</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$33.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Amit Dayal</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Chip Moore</td>
<td>Roth MKM</td>
<td>Maintains</td>
<td>Buy</td>
<td>$36.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Jeffrey Osborne</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$41.00</td>
<td>$36.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Aspen Aerogels. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Aspen Aerogels compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Aspen Aerogels's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Aspen Aerogels's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ASPN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Aspen Aerogels analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Aspen Aerogels</h2>
Aspen Aerogels Inc is an aerogel technology company that designs, develops, and manufactures high-performance aerogel insulation used in the energy industrial and sustainable insulation markets. The company also conducts research and development related to aerogel technology supported by funding from several agencies of the United States of America government and other institutions in the form of research and development contracts. It is engaged in two operating segment Energy Industrial and Thermal Barrier. Geographically, it operates in the U.S. and also has a presence in other International countries. It generates the majority of its revenue from the Energy Industrial segment and the United States market. Some of its products include Pyrogel XTE; Cryogel Z; Spaceloft Subsea; and others.
<h3>Aspen Aerogels: Financial Performance Dissected</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Aspen Aerogels's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 93.14%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Materials sector.
Net Margin: Aspen Aerogels's net margin is impressive, surpassing industry averages. With a net margin of -11.05%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Aspen Aerogels's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -2.53%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -1.69%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Aspen Aerogels's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.4.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Aspen Aerogels In The Eyes Of 6 Experts

Barclays analyst David Anderson maintains Aspen Aerogels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) with a Overweight and lowers the price target from $27 to $25.

Barclays Maintains Overweight on Aspen Aerogels, Lowers Price Target to $25

Roth MKM analyst Chip Moore maintains Aspen Aerogels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) with a Buy and lowers the price target from $36 to $31.

Roth MKM Maintains Buy on Aspen Aerogels, Lowers Price Target to $31

Aspen Aerogels Sees FT24 Revenue ~$450M

Aspen Aerogels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.08) by 112.5 percent. The company reported quarterly sales of $117.340 million which beat the analyst consensus estimate of $109.361 million by 7.30 percent. This is a 93.14 percent increase over sales of $60.755 million the same period last year.

Earnings Misses

Aspen Aerogels Q3 2024 GAAP EPS $(0.17) Misses $(0.08) Estimate, Sales $117.340M Beat $109.361M Estimate

Aspen Aerogels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) is gearing up to announce its quarterly earnings on Wednesday, 2024-11-06. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Aspen Aerogels will report an earnings per share (EPS) of $-0.08.
Anticipation surrounds Aspen Aerogels's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings Track Record</h3>
In the previous earnings release, the company beat EPS by $0.17, leading to a 16.0% increase in the share price the following trading session.
Here's a look at Aspen Aerogels's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.04</td>
<td>-0.11</td>
<td>-0.12</td>
<td>-0.30</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.21</td>
<td>-0.02</td>
<td>-0.01</td>
<td>-0.19</td>
</tr>
<tr>
<td>Price Change %</td>
<td>16.0%</td>
<td>56.99999999999999%</td>
<td>16.0%</td>
<td>11.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730833388_0.png" alt="eps graph" />
<h3>Performance of Aspen Aerogels Shares</h3>
Shares of Aspen Aerogels were trading at $18.25 as of November 04. Over the last 52-week period, shares are up 89.9%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<h3>Insights Shared by Analysts on Aspen Aerogels</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Aspen Aerogels.
The consensus rating for Aspen Aerogels is Buy, based on 6 analyst ratings. With an average one-year price target of $30.67, there's a potential 68.05% upside.
<h3>Comparing Ratings Among Industry Peers</h3>
The below comparison of the analyst ratings and average 1-year price targets of Ingevity, Valhi and Perimeter Solutions, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.
<ul>
<li>As per analysts' assessments, Ingevity is favoring an Neutral trajectory, with an average 1-year price target of $43.5, suggesting a potential 138.36% upside.</li>
<li>As per analysts' assessments, Valhi is favoring an Underperform trajectory, with an average 1-year price target of $20.0, suggesting a potential 9.59% upside.</li>
<li>The consensus outlook from analysts is an Neutral trajectory for Perimeter Solutions, with an average 1-year price target of $14.5, indicating a potential 20.55% downside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
The peer analysis summary outlines pivotal metrics for Ingevity, Valhi and Perimeter Solutions, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aspen Aerogels</td>
<td>Buy</td>
<td>144.55%</td>
<td>$51.58M</td>
<td>3.33%</td>
</tr>
<tr>
<td>Ingevity</td>
<td>Neutral</td>
<td>-15.49%</td>
<td>$129.90M</td>
<td>-42.94%</td>
</tr>
<tr>
<td>Valhi</td>
<td>Underperform</td>
<td>10.37%</td>
<td>$121.30M</td>
<td>2.10%</td>
</tr>
<tr>
<td>Perimeter Solutions</td>
<td>Neutral</td>
<td>67.17%</td>
<td>$73.27M</td>
<td>2.04%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Aspen Aerogels ranks highest in Revenue Growth among its peers, showing a significant increase. In terms of Gross Profit, Aspen Aerogels is at the top with a strong performance. However, its Return on Equity is moderate compared to others. Overall, Aspen Aerogels is positioned well compared to its peers in key financial metrics.
<h3>Unveiling the Story Behind Aspen Aerogels</h3>
Aspen Aerogels Inc is an aerogel technology company that designs, develops, and manufactures high-performance aerogel insulation used in the energy industrial and sustainable insulation markets. The company also conducts research and development related to aerogel technology supported by funding from several agencies of the United States of America government and other institutions in the form of research and development contracts. It is engaged in two operating segment Energy Industrial and Thermal Barrier. Geographically, it operates in the U.S. and also has a presence in other International countries. It generates the majority of its revenue from the Energy Industrial segment and the United States market. Some of its products include Pyrogel XTE; Cryogel Z; Spaceloft Subsea; and others.
<h3>Key Indicators: Aspen Aerogels's Financial Health</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Aspen Aerogels's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 144.55% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Materials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Aspen Aerogels's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 14.28% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Aspen Aerogels's ROE stands out, surpassing industry averages. With an impressive ROE of 3.33%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Aspen Aerogels's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.33%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.29.
<a href="https://www.benzinga.com/quote/ASPN/earnings">To track all earnings releases for Aspen Aerogels visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What's Next: Aspen Aerogels's Earnings Preview

Aspen Aerogels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) has outperformed the market over the past 5 years by 13.55% on an annualized basis producing an average annual return of 27.47%. Currently, Aspen Aerogels has a market capitalization of $1.57 billion. 
Buying $1000 In ASPN: If an investor had bought $1000 of ASPN stock 5 years ago, it would be worth $3,343.19 today based on a price of $20.36 for ASPN at the time of writing.
<h3>Aspen Aerogels's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729607605_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,300 Today

Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGS – AppLovin (APP)&nbsp;up 29.4% Dutch Bros&n...

Closing Bell Movers: Cisco gains 7%, Robinhood up 15% on earnings

Aspen Aerogels (ASPN – Research Report) received a Hold rating and price target from Seaport Global analyst Tom Curran yesterday. The company's sha...

Aspen Aerogels (ASPN) was downgraded to a Hold Rating at Seaport Global

Seaport Research downgraded Aspen Aerogels (ASPN) to Neutral from Buy after its Q4 earnings and below-consensus guidance. The firm's conviction in ...

Aspen Aerogels downgraded to Neutral from Buy at Seaport Research

Aspen Aerogels (ASPN) is down -22.2%, or -$2.61 to $9.14. Published first on TheFly – the ultimate source for real-time, market-moving breaking fin...

Aspen Aerogels falls -22.2%

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Cisco (CSCO) increased revenue 9% year...

Cisco jumps after earnings beat, Trump teases reciprocal tariffs: Morning Buzz

Aspen Aerogels (ASPN) is down -25.8%, or -$3.03 to $8.72. Published first on TheFly – the ultimate source for real-time, market-moving breaking fin...

Aspen Aerogels falls -25.8%

Jeff Osborne, an analyst from TD Cowen, maintained the Buy rating on Aspen Aerogels (ASPN – Research Report). The associated price target was lower...

Aspen Aerogels: Strategic Growth Positioning and Financial Resilience Earns Buy Rating

Aspen Aerogels, Inc. 2024 Q4 - Results - Earnings Call Presentation

Aspen Aerogels, Inc. (ASPN) Q4 2024 Earnings Call Transcript

Aspen Aerogels outlines $75M-$95M Q1 2025 revenue projection amid evolving EV and energy industrial dynamics

AAPL

AMZN

BPAQF

CROX

GEHC

HNDAF

TSLA

UPWK

Commodities

Press Releases

Aspen Aerogels, Inc. Announces New Appointment to its Board of Directors

Aspen Aerogels, Inc. Announces $125 Million Term Loan and $100 Million Revolving Credit Facility with MidCap Financial, and Full Cash Redemption of Legacy Convertible Note

Aspen Aerogels, Inc. Receives Conditional Commitment for Proposed DOE Loan and Provides Q3 2024 Preliminary Financial Results

Offerings

ASPEN AEROGELS, INC. ANNOUNCES PUBLIC OFFERING OF 4,250,000 SHARES OF COMMON STOCK

ASPEN AEROGELS, INC. ANNOUNCES PRICING OF PUBLIC OFFERING OF 4,250,000 SHARES OF COMMON STOCK

Aspen Aerogels, Inc. Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Aspen Aerogels, Inc. to Present at the Barclays 15th Annual Global Automotive and Mobility Tech Conference

Aspen Aerogels, Inc. Schedules Fourth Quarter and Fiscal Year 2024 Earnings Release and Conference Call

Aspen Aerogels Reaches Settlement with AMA to Resolve Patent Case

Aspen Aerogels, Inc. Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Business Highlights

Comments

Aspen Aerogels

Noticias

Últimas noticias sobre Aspen Aerogels (NYSE:ASPN) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL